Sandbox:Sahar: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
(4 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
{{familytree/start |summary=Sample 1}} | |||
{{familytree | | | | | E04 | | | | |E04=[[Infection]]/[[Inflammation]]}} | |||
{{familytree | | | | | |!| | | | }} | |||
{{familytree | | | | | E05 | | | | |E05=Increased production of [[IL-1]]/[[IL-6]]/[[TNF-α]]}} | |||
{{familytree | | | | | |!| | | | }} | |||
{{familytree | | | | | C05 | | | | |C05=Upregulation of [[hepatic]] serum amyloid A production}} | |||
{{familytree | | | | | |!| | | | | | }} | |||
{{familytree | | | | | C04 | | | | |C04=SAA production uptake by [[macrophages]]}} | |||
{{familytree | | | | | |!| | | | }} | |||
{{familytree | | | | | D05 | | | | |D05=C-terminal cleavage of SAA}} | |||
{{familytree | | | | | |!| | | | }} | |||
{{familytree | | | | | F01 | | | | |F01=β-sheet configuration of SAA}} | |||
{{familytree | | | | | |!| | | | }} | |||
{{familytree | | | | | G05 | | | | |G05=Fibril deposition in [[extracellular space]]}} | |||
{{familytree | | | | | |!| | | | }} | |||
{{familytree | | | | | H05 | | | | |H05=Binding of [[glycosaminoglycan]], serum amyloid P, and [[lipid]] components}} | |||
{{familytree | | | | | |!| | | | }} | |||
{{familytree | | | | | K05 | | | | |K05=Resistant to proteolysis}} | |||
{| | |||
! colspan="2" style="background:#DCDCDC;" align="center" + |The above algorithm is adopted from International Journal of Nephrology and Renovascular Disease<ref>{{cite journal |vauthors=Rumjon A, Coats T, Javaid MM |title=Review of eprodisate for the treatment of renal disease in AA amyloidosis |journal=Int J Nephrol Renovasc Dis |volume=5 |issue= |pages=37–43 |date=2012 |pmid=22427728 |pmc=3304340 |doi=10.2147/IJNRD.S19165 |url=}}</ref> | |||
|- | |||
|} | |||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ |
Revision as of 04:43, 10 November 2019
Infection/Inflammation | |||||||||||||||||||||||
Increased production of IL-1/IL-6/TNF-α | |||||||||||||||||||||||
Upregulation of hepatic serum amyloid A production | |||||||||||||||||||||||
SAA production uptake by macrophages | |||||||||||||||||||||||
C-terminal cleavage of SAA | |||||||||||||||||||||||
β-sheet configuration of SAA | |||||||||||||||||||||||
Fibril deposition in extracellular space | |||||||||||||||||||||||
Binding of glycosaminoglycan, serum amyloid P, and lipid components | |||||||||||||||||||||||
Resistant to proteolysis | |||||||||||||||||||||||
The above algorithm is adopted from International Journal of Nephrology and Renovascular Disease[1] |
---|
Organ System Involvement | Differential Diagnosis | Causes | Clinical Features | Laboratory Findings | Gold Standard Test | Therapy |
---|---|---|---|---|---|---|
Nephrotic Syndrome and Renal Failure | Secondary (AA) Amyloidosis |
|
|
|
|
|
Primary (AL) Amyloidosis |
|
|
|
|||
Diabetic Nephropathy |
|
|
|
|||
Minimal Change Disease |
|
| ||||
Focal Segmental Glomerulosclerosis | ||||||
Fabry's Disease |
|
|
|
|
| |
Light Chain Deposition Disease |
|
|
| |||
Membranous Glomerulonephritis |
|
|
|
|
| |
Fibrillary-Immunotactoid Glomerulopathy |
|
|
|
|||
Organ System Involvement | Differential Diagnosis | Causes | Clinical Features | Laboratory Findings | Gold Standard Test | Therapy |
Polyneuropathy | POEMS syndrome (Demyelinating) |
|
|
|||
Metabolic Syndrome (Axonal pathology) |
|
|
|
|||
Vitamin Deficiencies (Axonal Pathology) |
|
|
|
| ||
Guillain-Barre Syndrome (Demyelinating) |
|
|
|
|||
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Mixed axonal and demyelinatiing) |
|
|
|
|
||
Multifocal Motor Neuropathy |
|
|||||
Organ System Involvement | Differential Diagnosis | Causes | Features | Laboratory Findings | Gold Standard Test | Therapy |
Organomegaly (Hepatosplenomegaly and Lymphadenopathy) | Malaria |
|
|
| ||
Kala-azar |
|
|
|
|||
Infective Hepatitis |
|
|
||||
Chronic Myelogenous Leukemia (CML) |
|
|
||||
Lymphoma |
|
|
||||
Primary (AL) Amyloidosis |
|
|
|
| ||
Gaucher's Disease |
|
|
|
|
Example #1
The patient presented with S.O.B. one year after hysterectomy for a leiomyomatous uterus.
- ↑ Rumjon A, Coats T, Javaid MM (2012). "Review of eprodisate for the treatment of renal disease in AA amyloidosis". Int J Nephrol Renovasc Dis. 5: 37–43. doi:10.2147/IJNRD.S19165. PMC 3304340. PMID 22427728.